- Clinical need
- About microRNA
- Test technology
- How the test is performed
- For which patients
- Today's Diagnostic Solution
- Results overview
- How to order
- News and publications
- miRview® home
The next generation of
cancer diagnostics is here
cancer diagnostics is here
Introducing miRview® mets2/mets
Rosetta Genomics is pleased to introduce
the next generation of cancer diagnostics: microRNA assays.
miRview® mets - a microRNA-based test able to identify primary origins of metastases from a panel of 25 different tumors.
NEW miRview® mets2 - a second generation version of miRviewm® mets, featuring an expanded panel of 42 identifiable origins, and improved classifers
|
miRview® mets and miRview® mets2 are the first microRNA-based tests for identifying the origin of metastatic tumors, designed for cancer patients with unknown or uncertain primary origins. The test offers:
|
|
||||||||
